Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of ...

On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) ...

Studies of the consequences of BAFF overexpression have been complemented by studies investigating the effects of blocking either BAFF or both BAFF and APRIL (a proliferation inducing ligand, also ...

Novartis also has an anti-APRIL antibody called zigakibart in phase 3 trials, while Vertex Pharma has a dual antagonist of BAFF and APRIL, povetacicept, which it acquired as part of its takeover ...